Navigation Links
Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Date:11/6/2008

663.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has five product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, has completed one Phase 3 clinical trial and enrolled a second Phase 3 trial. The Company has completed its end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine), which is intended for the acute treatment of migraine headache, and it has advanced AZ-104 (Staccato loxapine) to Phase 2 testing. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. In addition, AZ-002 (Staccato alprazolam) has completed a Phase 2a proof-of-concept clinical trial for the treatment of panic attacks -- an indication the Company is not planning to pursue -- and is being assessed for other possible indications and renewed clinical development. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
2. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
3. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
4. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
5. Alexza to Webcast Investor and Analyst Day Presentations
6. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
7. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 The report ... provides comprehensive information on the therapeutic development ... pipelines by identifying new targets and MOAs ... report on H1 2015 pipeline review of ... and 13 figures, spread across 47 pages ...
(Date:5/29/2015)... 29, 2015 The popular all-natural supplement ... rewards based L-Style Select Program that gives bonuses to ... limited to only 100 members per year, lucky members ... on one with fitness experts at Nuretix Research, and ... them provided that they attain and maintain their weight ...
(Date:5/29/2015)... For the third year, Nike Ultimate Camps will ... ultimate community an opportunity to experience ultimate training techniques in ... of the USAU Nike Ultimate Camp is to provide a ... character, and make lifelong friends. , The USAU Nike Ultimate ... skill and ability levels, ages 10-18. Camp will run from ...
(Date:5/29/2015)... Health DataPalooza is a national conference ... and foster the most effective and innovative ways to ... is hosted by the Health Data Consortium, which is ... promote and develop the use of open healthcare data. ... to narrow in on how to actually put the ...
(Date:5/29/2015)... NEW YORK (PRWEB) May 29, 2015 ... Medical Center has found that a urine test ... cancer with 92 percent accuracy. Dr. James McKiernan ... 2015 Annual Meeting Press Event. , Dr. ... John K. Lattimer Professor and chair of the ...
Breaking Medicine News(10 mins):Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 3Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 3
... some experts, newly born neuronal stem cells in the adult ... these stem cells are to be utilized in this way, ... regulated. , A new study, led by Laurence Katz, ... of the North Carolina School of Medicine, suggests a way ...
... FALLS" , A study by Indiana University ... of their elderly study participants and their postural stability ... in line with recent findings by other researchers involving ... designed to probe cognitive function effective at identifying people ...
... of American,Physicians, Inc. (CAP) today announced that the exceptional ... has again,earned an A+ rating from A.M. Best Company, ... consecutive year that MPT has,achieved this rating., "We ... Rating again this year,",said CEO James L. Weidner. "It ...
... to millions of diabetics who are missed , , FRIDAY, ... for diabetes is being called for to help the ... disease, a new report says. , "Approximately 30 percent ... undiagnosed," study author Dr. Christopher Saudek, of Johns Hopkins ...
... & Asthma Network Mothers of Asthmatics Applauds FDA Public ... and Offers Critical Facts Patients Need to Know, ... their healthcare providers do not know that at the ... Today, FDA urged patients,still using chlorofluorocarbon (CFC) albuterol metered-dose ...
... EXTON, Pa., May 30 Isolagen(TM), Inc. (Amex:,ILE) ... notice from the staff,of the American Stock Exchange (AMEX) ... compliance did not demonstrate its ability,to regain compliance with ... (a)(i)-(iii) of the AMEX Company Guide within the,prescribed time ...
Cached Medicine News:Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2Health News:Panel Calls for Better Diabetes Screening 2Health News:Get the Facts on the Albuterol Inhaler Transition 2Health News:Get the Facts on the Albuterol Inhaler Transition 3Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3
(Date:5/29/2015)... and BOSTON , May ... in instrument development, custom automation, and contract manufacturing, and ... the Nanopatch™ needle-free drug delivery technology, have been named ... of the Nanopatch Jet Coating Instrument , an ... research and product development.  The award was announced last ...
(Date:5/29/2015)... Research and Markets ( ... "Surgical/Operating Microscopes Market by Application & End ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... poised to reach $806.6 million by 2020 from ... 12.3% from 2015 to 2020. , ,Major factors ...
(Date:5/29/2015)... , May 29, 2015 /CNW/ - Covalon Technologies Ltd. ... medical technologies company, is delighted to announce its ... 31, 2015, which includes revenue for three months ... of $264,340. Revenue from advanced wound care product sales ... 2015 increased 24% to $1,742,672 compared to $1,400,065 ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3
... BioWa, Inc. announced today that it has entered into ... Tokyo based Astellas Pharma Inc., providing Agensys with access ... purpose of identifying antibodies with enhanced antibody-dependent cellular cytotoxicity ... our Agreement with Agensys, a leading monoclonal antibody organization ...
... TORONTO and BASEL, Switzerland, Nov. 15, 2010 ... co-operation created to provide clients with geographically diversified, ... production of active pharmaceutical ingredients. In ... capital efficiency, pharmaceutical development companies have been seeking ...
Cached Medicine Technology:BioWa Announces License of POTELLIGENT® Technology to Agensys 2Dalton and Lonza Announce Co-operation to Provide Contract Chemistry Services and Manufacturing 2Dalton and Lonza Announce Co-operation to Provide Contract Chemistry Services and Manufacturing 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: